Stem definition | Drug id | CAS RN |
---|---|---|
humanized origin | 5308 | 915810-67-2 |
Molecule | Description |
---|---|
Synonyms:
|
In patients with aTTP, levels of a substance called von Willebrand factor are increased. von Willebrand factor acts on platelets to cause them to stick together and form blood clots. Caplacizumab, the active substance in Cablivi, is a nanobody (a small antibody) which has been designed to attach to von Willebrand factor in a way that stops it acting on platelets. This reduces platelets sticking together and forming clots in blood vessels and, as a result, platelet levels in the blood rise because they are no longer taken up to form clots.
|
Dose | Unit | Route |
---|---|---|
10 | mg | P |
None
Date | Agency | Company | Orphan |
---|---|---|---|
Aug. 30, 2018 | EMA | ABLYNX NV | |
Feb. 6, 2019 | FDA | ABLYNX NV |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
ADAMTS13 activity decreased | 152.45 | 54.81 | 17 | 415 | 89 | 56291546 |
ADAMTS13 activity abnormal | 86.30 | 54.81 | 8 | 424 | 0 | 56291635 |
Thrombotic thrombocytopenic purpura | 73.00 | 54.81 | 14 | 418 | 3703 | 56287932 |
Platelet count decreased | 58.59 | 54.81 | 24 | 408 | 106359 | 56185276 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
ADAMTS13 activity abnormal | 92.01 | 79.07 | 8 | 114 | 0 | 31697222 |
Thrombotic thrombocytopenic purpura | 84.86 | 79.07 | 14 | 108 | 3299 | 31693923 |
ADAMTS13 activity decreased | 82.73 | 79.07 | 9 | 113 | 82 | 31697140 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
ADAMTS13 activity decreased | 182.56 | 47.87 | 21 | 530 | 149 | 70927744 |
ADAMTS13 activity abnormal | 140.11 | 47.87 | 13 | 538 | 0 | 70927893 |
Thrombotic thrombocytopenic purpura | 89.03 | 47.87 | 18 | 533 | 6159 | 70921734 |
Platelet count decreased | 55.19 | 47.87 | 27 | 524 | 178195 | 70749698 |
None
Source | Code | Description |
---|---|---|
ATC | B01AX07 | BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Other antithrombotic agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Thrombotic thrombocytopenic purpura | indication | 78129009 | DOID:10772 |
None
None
None
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
von Willebrand factor | Unclassified | ANTIBODY BINDING | Kd | 8.51 | IUPHAR | DRUG LABEL |
ID | Source |
---|---|
2R27AB6766 | UNII |
C3713057 | UMLSCUI |
CHEMBL2109624 | ChEMBL_ID |
DB06081 | DRUGBANK_ID |
D11160 | KEGG_DRUG |
9511 | INN_ID |
9123 | IUPHAR_LIGAND_ID |
36266 | MMSL |
d09171 | MMSL |
017896 | NDDF |
784411004 | SNOMEDCT_US |
789447000 | SNOMEDCT_US |
4038197 | VANDF |
4038198 | VANDF |
C585343 | MESH_SUPPLEMENTAL_RECORD_UI |
2110604 | RXNORM |
None